REG - Shield Therapeutics - Results of 2024 Annual General Meeting

Shield TherapeuticsAnnouncement

20/06/2024 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240620:nRST2805Ta&default-theme=true

RNS Number : 2805T  Shield Therapeutics PLC  20 June 2024

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Results of 2024 Annual General Meeting

 

London, UK, 20 June 2024: Shield Therapeutics plc (LSE: STX), a commercial
stage pharmaceutical company that delivers Accrufer®/Feraccru® (ferric
maltol), an innovative and differentiated specialty pharmaceutical product, to
address a significant unmet need for patients suffering from iron deficiency
(with or without anaemia), announces the voting results for each resolution
set out in the Notice of Annual General Meeting 2024. The Board reports that
all resolutions were passed: 1 to 10 passed as ordinary resolutions and 11 to
12 passed as special resolutions.

 

The following table shows the votes cast on each resolution:

 

                VOTES        %       VOTES AGAINST  %      WITHHELD VOTES

FOR
 Resolution 1   371,135,672  99.65%  1,321,765      0.35%  387,002
 Resolution 2   367,256,140  98.70%  4,821,667      1.30%  766,632
 Resolution 3   368,781,407  99.11%  3,296,400      0.89%  766,632
 Resolution 4   368,781,161  99.11%  3,296,646      0.89%  766,632
 Resolution 5   369,852,377  99.40%  2,225,430      0.60%  766,632
 Resolution 6   369,852,377  99.39%  2,266,765      0.61%  725,297
 Resolution 7   368,193,486  98.96%  3,884,321      1.04%  766,632
 Resolution 8   371,077,210  99.63%  1,380,227      0.37%  387,002
 Resolution 9   370,260,710  99.38%  2,293,669      0.62%  290,060
 Resolution 10  368,304,167  98.90%  4,079,150      1.10%  461,122
 Resolution 11  368,067,995  98.84%  4,305,730      1.16%  470,714
 Resolution 12  367,071,290  98.53%  5,470,921      1.47%  302,228

 

Notes:

1.    Number of shares in issue 782,056,367.

2.    Details of the votes received on the resolutions are available on the
Company's website:

https://www.shieldtherapeutics.com/corporate-documents/
(https://www.shieldtherapeutics.com/corporate-documents/) .

3.    Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.

 

For further information please contact:

 

 Shield Therapeutics plc                                                                        www.shieldtherapeutics.com (http://www.shieldtherapeutics.com/)
 Greg Madison, CEO                                                                              +44 (0) 191 511 8500

 Santosh Shanbhag, CFO

 Nominated Adviser and Joint Broker
 Peel Hunt LLP
 James Steel / Patrick Birkholm                                                                 +44 (0)20 7418 8900

 Joint Broker

 Cavendish Ltd

 Geoff Nash / George Dollemore/ Nigel Birks /Harriet
 Ward

                                                                                                +44 (0)20 7220 0500

 Financial PR & IR Advisor
 Walbrook PR
 Charlotte Edgar / Alice Woodings                                                               +44 (0)20 7933 8780 or shield@walbrookpr.com (mailto:shield@walbrookpr.com)

 Investor Contact (US Advisor)

 LifeSci Advisors, LLC

 Joyce Allaire                                                                                  jallaire@lifesciadvisors.com (mailto:jallaire@lifesciadvisors.com)

 

About Iron Deficiency and Accrufer®/Feraccru®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health
problems for adults of all ages, across multiple therapeutic areas. Together,
ID and ID with anaemia (IDA) affect about 20 million people in the U.S. and
represent a $2.3B market opportunity. As the first and only FDA approved oral
iron to treat ID/IDA, Accrufer® has the potential to meet an important unmet
medical need for both physicians and patients.

 

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt-based oral
therapy for adults with ID/IDA. Accrufer®/Feraccru® has a novel mechanism of
absorption compared to other oral iron therapies and has been shown to be an
efficacious and well-tolerated therapy in a range of clinical trials. More
information about Accrufer®/Feraccru®, including the product label, can be
found at: www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com) .

 

About Shield Therapeutics plc

Shield is a commercial-stage specialty pharmaceutical company that delivers
Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated
pharmaceutical product, to address a significant unmet need for patients
suffering from iron deficiency, with or without anaemia. The Company has
launched Accrufer® in the U.S. with an exclusive, multi-year commercial
agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has
licensed the rights to four specialty pharmaceutical companies. Feraccru® is
commercialised in the UK and European Union by Norgine B.V. (Norgine), which
also has marketing rights in Australia and New Zealand. Shield also has an
exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd.
for the development and commercialisation of Accrufer®/ Feraccru® in China,
Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of
Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada. To learn
more about Shield Therapeutics, see our website at www.shieldtherapeutics.com
(http://www.shieldtherapeutics.com) or follow us on LinkedIn and X.

 

Accrufer®/Feraccru® has patent coverage until the mid-2030s.

Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGZZGZVKGDGDZM